Allogene Therapeutics, Inc. (NASDAQ:ALLO) SVP Sells $10,866.24 in Stock

Allogene Therapeutics, Inc. (NASDAQ:ALLO) SVP Benjamin Machinas Beneski sold 5,488 shares of the company’s stock in a transaction on Friday, March 14th. The stock was sold at an average price of $1.98, for a total transaction of $10,866.24. Following the transaction, the senior vice president now owns 218,507 shares of the company’s stock, valued at $432,643.86. This trade represents a 2.45 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Allogene Therapeutics Trading Down 3.6 %

Shares of ALLO opened at $1.63 on Friday. The stock has a market capitalization of $354.14 million, a P/E ratio of -1.04 and a beta of 1.02. The firm’s fifty day simple moving average is $1.89 and its two-hundred day simple moving average is $2.29. Allogene Therapeutics, Inc. has a 12 month low of $1.32 and a 12 month high of $4.63.

Allogene Therapeutics (NASDAQ:ALLO) last issued its quarterly earnings results on Thursday, March 13th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.06. As a group, research analysts predict that Allogene Therapeutics, Inc. will post -1.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. Canaccord Genuity Group reissued a “buy” rating and issued a $14.00 price objective on shares of Allogene Therapeutics in a research note on Friday, March 14th. Royal Bank of Canada reissued an “outperform” rating and issued a $10.00 price objective on shares of Allogene Therapeutics in a research note on Friday, March 14th. HC Wainwright reduced their price objective on shares of Allogene Therapeutics from $9.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday. Finally, Citizens Jmp raised shares of Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price objective on the stock in a research note on Friday, March 14th. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $9.29.

Hedge Funds Weigh In On Allogene Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in ALLO. Cibc World Markets Corp bought a new position in shares of Allogene Therapeutics during the 4th quarter worth about $26,000. PAX Financial Group LLC bought a new position in shares of Allogene Therapeutics during the 4th quarter worth about $27,000. RPO LLC bought a new position in shares of Allogene Therapeutics during the 4th quarter worth about $31,000. Caption Management LLC bought a new position in shares of Allogene Therapeutics during the 4th quarter worth about $32,000. Finally, Syon Capital LLC bought a new position in shares of Allogene Therapeutics during the 4th quarter worth about $39,000. Institutional investors own 83.63% of the company’s stock.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).